Figure 2: Retrospective Cohort Study Design
2019-06-11T07:00:41Z (GMT) by
The retrospective clinical analysis described here was designed based on the approval and clinical trial history of celecoxib. Celecoxib was approved on December 31, 1998, and clinical trial results revealed a potential cardiovascular risk in early 2005, defining our drug surveillance period. Body mass index (BMI) data were collected within 1 year of January 1, 2005. The aortic stenosis surveillance period extended from January 1, 2005, to January 27, 2018. APC = Adenoma Prevention With Celecoxib; FDA = Food and Drug Administration.